Marinus Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
40.53 M |
Public Float |
37.51 M |
Marinus Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.99 |
Market Cap |
$234.4 M |
Shares Outstanding |
52.56 M |
Public Float |
43.98 M |
Address |
170 North Radnor Chester Road Radnor Pennsylvania 19087 United States |
Employees | - |
Website | http://www.marinuspharma.com |
Updated | 07/08/2019 |
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. |